22.7 C
Vientiane
Monday, May 12, 2025
spot_img
Home Blog Page 1913

Spackman Media Group Artist Son Suk-Ku Wins JTBC Grand Prize At The 2022 TV Drama Acting Awards In Korea 

  • Spackman Media Group artist Son Suk-ku received the JTBC Grand Prize at the 2022 TV Drama Acting Awards held by Good Data Corporation in Korea on December 31, 2022
  • Award underscores the star power and popularity of Son Suk-ku, whose latest hit drama, BIG BET, ranked first in the Top 10 TV Shows on Disney+ Korea as of January 1, 2022
  • Looking ahead, Son Suk-ku is set to star in two upcoming highly anticipated Netflix original K-dramas, D.P. SEASON 2 and MURDEROUS TOY.

SINGAPORE – Media OutReach – 2 January 2023 – Spackman Entertainment Group Limited (the “Group“), one of Korea’s leading entertainment production groups founded in 2011 by media & technology investor Charles Spackman, wishes to announce that Son Suk-ku of the Group’s associated company, Spackman Media Group Limited (“Spackman Media Group“), was awarded the JTBC Grand Prize at the 2022 TV Drama Acting Awards held by Good Data Corporation in Korea on December 31, 2022.

Good Data Corporation is an online competitive analysis agency for K-content in Korea. The 2022 TV Drama Acting Awards is based on the results of aggregating the weekly ranking points of every actor who appeared in the 119 dramas that aired from January 1, 2022 to December 24, 2022, for each major broadcasting station. The ranking points were derived from drama-related information generated on social media and netizens’ reactions to the drama.

The JTBC Grand Prize received by Spackman Media Group artist Son Suk-ku serves as a testament to his star power and popularity in Korea. His latest hit drama, BIG BET, ranked in the Top 10 TV Shows on Disney+ Korea as of January 1, 2022.[1]

BIG BET is an 8-episode drama series, which premiered exclusively on Disney+ on December 21, 2022, and airs every Wednesday. Headlined by Spackman Media Group artist Son Suk-ku, Choi Min Shik, Heo Sung Tae, Kim Joo Ryung, Lee Dong Hwi and Jo Jae Yoon, it relates the eventful life of a man who gains success through the casino industry.

Directed by Kang Yoon Sung of the 2017 box office hit THE OUTLAWS, which was co-presented and distributed by the Group’s subsidiary, Novus Mediacorp Co., Ltd., BIG BET was produced by BA Entertainment, C-Jes Entertainment and Arc Media.

Looking ahead, Son Suk-ku is set to star in two upcoming highly anticipated Netflix original K-dramas, D.P. SEASON 2 and MURDEROUS TOY. He is represented by SBD Entertainment Inc. (“SBD Entertainment“), a wholly-owned subsidiary of Spackman Media Group that represents and manages the careers of 12 artists. In addition to Son Suk-ku, SBD Entertainment also represents one of Korea’s rapidly rising young actors, Han Ji-hyun of popular K-drama THE PENTHOUSE 3, who won the Best Rookie Female Actor in the 2021 Brand Customer Loyalty Awards in Korea and endorsed luxury brand Gucci in April 2021.


[1] FlixPatrol, https://flixpatrol.com/top10/streaming/south-korea/2023-01-01/, TOP 10 on Disney+ in South Korea on January 1, 2023

Hashtag: #SpackmanEntertainmentGroup

The issuer is solely responsible for the content of this announcement.

About Spackman Entertainment Group Limited

Spackman Entertainment Group Limited (“SEGL” or the “Company“), and together with its subsidiaries, (the “Group“), is one of Korea’s leading entertainment production groups. SEGL is primarily engaged in the independent development, production, presentation, and financing of theatrical motion pictures in Korea.

The Company was founded in 2011 by renowned media and technology investor Charles Spackman who served as the Company’s Executive Chairman until 2017. For the past two decades, Mr. Charles Spackman has been a powerhouse in the Korean entertainment industry starting in the early 2000’s with the pioneering success of Sidus Pictures, the largest movie production company at the time and the first to be listed in Korea. Mr. Spackman is also the Founder, Chairman and Chief Executive Officer of the global investment firm, Spackman Group. For more information, please visit and .

Since its founding, SEGL had produced more than 30 major motion pictures including a number of the highest grossing and award-winning films in Korea, namely #ALIVE (2020), CRAZY ROMANCE (2019), DEFAULT (2018), MASTER (2016), THE PRIESTS (2015), SNOWPIERCER (2013), COLD EYES (2013) and ALL ABOUT MY WIFE (2012).

Our films are theatrically distributed and released in Korea and overseas markets, as well as for subsequent post-theatrical worldwide release in other forms of media, including online streaming, cable TV, broadcast TV, IPTV, video-on-demand, and home video/DVD, etc. Generally, we release our motion pictures into wide-theatrical exhibition initially in Korea, and then in overseas and ancillary markets.

The Group also invests into and produces Korean television dramas. In addition to our content business, we also own equity stakes in entertainment-related companies and film funds that can financially and strategically complement our existing core operations. SEGL is listed on the Catalist of the Singapore Exchange Securities Trading Limited under the ticker 40E.

Production Labels

SEGL owns a 100% equity interest in Studio Take Co., Ltd. (“Studio Take“) which produced STONE SKIPPING (2020) and THE BOX (2021). Its latest film, A MAN OF REASON, is set to be screened theatrically and digitally in North America in the first quarter of 2023 and at theatres in Korea in the fourth quarter of 2022 or first quarter of 2023. A MAN OF REASON premiered in the US at the 42nd Hawaii International Film Festival. The film was also invited to the 47th Toronto International Film Festival, the largest film festival in North America, and the 55th Sitges Film Festival, one of the world’s top three genre film festivals. Studio Take shall also release an upcoming film, THE GUEST, in 2023 tentatively.

SEGL owns Novus Mediacorp Co., Ltd. (“Novus Mediacorp“), an investor, presenter, and/or post-theatrical distributor for a total of 80 films (59 Korean and 21 foreign) including OKAY MADAM (2020), LONG LIVE THE KING (2019), MY FIRST CLIENT (2019), ROSE OF BETRAYAL (2018), THE OUTLAWS (2017) and SECRETLY, GREATLY (2013), which was one of the biggest box office hits of 2013 starring Kim Soo-hyun of MY LOVE FROM THE STARS (2013), as well as FRIEND 2: THE GREAT LEGACY (2013). In 2012, Novus Mediacorp was also the post-theatrical rights distributor of ALL ABOUT MY WIFE (2012), a top-grossing romantic comedy produced by Zip Cinema. In 2018, THE OUTLAWS, co-presented by Novus Mediacorp broke the all-time highest Video On Demand (“VOD“) sales records in Korea. For more information, please visit

The Company owns a 100% equity interest in Greenlight Content Limited (“Greenlight Content“) which is mainly involved in the business of investing into dramas and movies, as well as providing consulting services for the production of Korean content. Through the acquisition of Greenlight Content, the Group’s first co-produced drama, MY SECRET TERRIUS, starring top Korean star, So Ji Sub, achieved #1 in drama viewership ratings for its time slot and recorded double digits for its highest viewership ratings. Greenlight Content was one of the main investors of MY SECRET TERRIUS.

The Company owns a 100% equity interest in Simplex Films Limited (“Simplex Films“) which is an early stage film production firm. The maiden film of Simplex Films, JESTERS: THE GAME CHANGERS (2019), was released in Korea on 21 August 2019. Simplex Films has several line-up of films including HURRICANE BROTHERS (working title).

The Company owns a 20% equity interest in The Makers Studio Co. Ltd., which plans to produce and release four upcoming films, the first of which will be THE ISLAND OF THE GHOST’S WAIL, a comedy horror film.

Talent Representation

The Company holds an effective shareholding interest of 43.88% in Spackman Media Group Limited (“SMGL“). SMGL, a company incorporated in Hong Kong, together with its subsidiaries, is collectively one of the largest entertainment talent agencies in Korea in terms of the number of artists under management, including some of the top names in the Korean entertainment industry. SMGL operates its talent management business through renowned agencies such as SBD Entertainment Inc. (Son Suk-ku, Han Ji-hyun, Park Keun-rok), MSteam Entertainment Co., Ltd. (Son Ye-jin, Wi Ha-jun, Lee Min-jung, Ko Sung-hee, Lee Cho-hee), UAA&CO Inc. (Kim Sang-kyung) and Play Content Co., Ltd. (Hwang-hwi). Through these full-service talent agencies in Korea, SMGL represents and guides the professional careers of a leading roster of award-winning actors/actresses in the practice areas of motion pictures, television, commercial endorsements, and branded entertainment. SMGL leverages its unparalleled portfolio of artists as a platform to develop, produce, finance and own the highest quality of entertainment content projects, including theatrical motion pictures, variety shows and TV dramas. This platform also creates and derives opportunities for SMGL to make strategic investments in development stage businesses that can collaborate with SMGL artists. SMGL is an associated company of the Company. For more information, please visit

The Company owns a 100% equity interest in Constellation Agency Pte. Ltd. (“Constellation Agency“). Constellation Agency, which owns The P Factory Co., Ltd. (“The P Factory“) and Platform Media Group Co., Ltd. (“PMG“), is primarily involved in the business of overseas agency for Korean artists venturing into the overseas market. The P Factory is an innovative marketing solutions provider specializing in event and branded content production. PMG is a talent management agency which represents and manages the careers of major artists in film, television, commercial endorsements and branded entertainment.

Strategic Businesses

The Company also operates a café-restaurant, Upper West, in the Gangnam district of Seoul and own a professional photography studio, noon pictures Co., Ltd.

For more details, please visit

Travel in Prosperity this Lunar New Year with Bread Garden’s CNY Goodies Collection for 2023

SINGAPORE – Media OutReach – 2 January 2023 – Usher in good health, wealth and happiness in the Year of the Rabbit with Bread Garden’s collection of delectable Chinese New Year goodies for 2023!

breadgarden-CNY-2023.png

Featuring an ensemble cast of familiar signature items, all-time favourites and innovative new bakes, the CNY treats from Bread Garden offer pure indulgence of both classic tastes and new flavours for you and your whole family.

A much-beloved brand among lovers of Chinese New Year festive snacks, Bread Garden continues to serve up high-quality and delicious bakes that have delighted both Singaporeans and oversea fans for the past 4 decades without fail.

A Journey of Abundance with Bread Garden’s Bountiful Goodies Box

With the lifting of covid restrictions and travelling returning with aggressive fervour, Bread Garden shares in the joy of adventure with this year’s travel-themed CNY gift set, specially designed as a cute-looking mini luggage bag, so that you can bring your favourite Chinese New Year treats on the go with you during festive visitations!

Aptly named Bountiful Goodies Box, each luggage gift set packs a full suite of the six most recommended snack flavours – in exquisitely designed metal cases, symbolising blessings in the six aspects of a life filled with abundance, making this the ideal gift for family and friends this Lunar New Year.

Signature CNY Goodies, Classics and New Flavours

Celebrating traditions is an integral part of Chinese New Year, which extends to the food we indulge in during this festive period.

This year, Bread Garden has again put together a diverse collection of CNY goodies featuring a mix of best-selling favourites, old-school classics, and innovative new flavours.

Returning to the lineup are all-time favourites like the Premium Pineapple Tart, Macadamia Buttery Cookies, and Melting Peanut Cookies, which continue to be in high demand year after year.

Of course, we can’t do without the established classics like Kueh Bangkit, Old School Almond Cookies, and Spicy Shrimp Rolls which are simply a must-have for any CNY celebration.

In recent years, bakeries have been experimenting with new and interesting flavours to appeal to a younger generation of snack buyers, and Bread Garden is at the forefront of this trend, always experimenting with new recipes and ingredients to introduce even more delectable creations for all to enjoy during Chinese New Year.

This year, new flavours include Choco Peanut Lava, for those who enjoy the gooey melting sensation of peanut butter oozing at the first bite, and Almond De Coco, a fragrant and scentful treat filled with fresh coconut goodness.

Exclusive Online Promotion for CNY Goodies

Enjoy up to 15% savings on your CNY goodies order with Bread Garden’s Buy 6 Get 1 Free exclusive online promotion (conditions apply) and $8 off each Bountiful Goodies Box, available now till sold out.

The full range of Bread Garden’s Chinese New Year goodies for 2023 is now available for sale at https://www.breadgarden.com.sg/cny-chinese-new-year-goodies/.

Hashtag: #BreadGarden

The issuer is solely responsible for the content of this announcement.

About Bread Garden

Bread Garden is a Singapore halal-certified bakery brand known for its popular festive goodies during Chinese New Year and the Mooncake Festival, as well as its selection of flavourful customised cakes and pastries.

Rated five stars consistently by customers on social media, Bread Garden stands out from other bakeries with its emphasis on quality over quantity, dedicating itself to producing only the best quality baked products that its customers have come to expect and love.

For more information on Bread Garden, visit .

FIGS FINAL DEADLINE ALERT: ROSEN, A HIGHLY RECOGNIZED LAW FIRM, Encourages FIGS, Inc. Investors with Losses Exceeding $100K to Secure Counsel Before Important January 3 Deadline in Securities Class Action – FIGS

New York, New York – Newsfile Corp. – December 30, 2022 – WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the stock of FIGS, Inc. (NYSE: FIGS): (i) pursuant and/or traceable to the registration statement and related prospectus issued in connection with the Company’s 2021 initial public offering (the “IPO” or “Offering”); and/or (ii) between May 27, 2021 and May 12, 2022, both dates inclusive (the “Class Period”), of the important January 3, 2023 lead plaintiff deadline.

SO WHAT: If you purchased FIGS securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

WHAT TO DO NEXT: To join the FIGS class action, go to https://rosenlegal.com/submit-form/?case_id=9629 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than January 3, 2023. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources or any meaningful peer recognition. Many of these firms do not actually handle securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

DETAILS OF THE CASE: According to the lawsuit, the registration statement supporting the IPO and defendants’ statements throughout the Class Period were false and/or misleading and/or failed to disclose that defendants: (1) inflated FIGS’ true ability to successfully secure repeat customers; (2) failed to disclose FIGS’ increasing dependence on air freight; and (3) inflated the expected net revenues, gross margin, and adjusted EBITDA margin for 2022. When the true details entered the market, the lawsuit claims that investors suffered damages.

To join the FIGS class action, go to https://rosenlegal.com/submit-form/?case_id=9629 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor’s ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Attorney Advertising. Prior results do not guarantee a similar outcome.

——————————-

Contact Information:

Laurence Rosen, Esq.
Phillip Kim, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 40th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
lrosen@rosenlegal.com
pkim@rosenlegal.com
cases@rosenlegal.com
www.rosenlegal.com

The issuer is solely responsible for the content of this announcement.

Yanchang Petroleum International Gains Approval for the New Supply Agreement with Its Parent Company

Bolstering the development of oil product business in the post-pandemic era

HONG KONG SAR – Media OutReach – 30 December 2022 – Yanchang Petroleum International Limited (“Yanchang Petroleum International” or the “Company”; stock code: 346.HK) is pleased to announce its subsidiary Henan Yanchang Petroleum Sales Co., Limited (“Henan Yanchang”) will enter into a new supply agreement with Shaanxi Yanchang Petroleum (Group) Co., Limited (“Yanchang Group”). The agreement has been approved by its shareholders at the Special General Meeting held today. Pursuant to which, Yanchang Group will supply refined oil and by-products to Henan Yanchang for three years ending 31 December 2025.

Henan Yanchang entered into a three-year supply agreement with Yanchang Group in 2019. The new agreement will maintain a reliable supply source to enhance the flexibility of business operations. As the economy in the PRC will gradually recover in the post-pandemic era, the Company expects that product demand will shortly return to the pre-pandemic level and the uptrend to continue. The Company believes that the scale of the oil product sales business in the PRC can be further expanded with the stable product supply, strengthening the Group’s profitability.

Mr. Feng Yinguo, Chairman of Yanchang Petroleum International, said, “Yanchang Group is one of the four largest state-owned oil and gas enterprises in the PRC. The new supply agreement will provide greater growth momentum for the Company’s oil product sales business in China. Going forward, the Company will continue to optimize the business of Henan Yanchang and further plan and expand its sales network, in order to expand the overall scale of the Company’s business and increase its competitiveness, creating greater value for our shareholders.”

Yanchang Group is the substantial shareholder of Yanchang Petroleum International, holding approximately 69.19% of the existing issued share capital of the Company. Henan Yanchang is an indirect non-wholly owned subsidiary of the Company, principally engaged in the business of wholesale, retail, storage and transportation of refined oil and by-products.

Hashtag: #YanchangPetroleum

The issuer is solely responsible for the content of this announcement.

About Yanchang Petroleum International Limited (Stock Code: 346.HK)

Yanchang Petroleum International is principally engaged in exploration, exploitation, and operation of oil and gas; and fuel oil trading and distribution. In its upstream operations, Yanchang Petroleum International possesses operating oilfields in Saskatchewan and Alberta, Canada, through its wholly owned subsidiary Novus Energy Inc., a Canadian enterprise. Novus engages in the business of acquiring, exploring for, developing and producing crude oil and natural gas. In its downstream operations, Yanchang Petroleum International is principally engaged in wholesale, retail, storage and transportation of oil products through its 70% owned subsidiary, Henan Yanchang Petroleum Sales Co., Limited, and which has been granted valid licenses for distribution and sales of oil products in China. The Group also established oil products trading companies in Zhoushan, Zhejiang and Shenzhen, China, respectively, for expanding its oil products trading business which become a new profit driver.

For details, please refer to

Southern Asset Management Asia-Pacific Low Carbon ETF launches today

SHENZHEN, CHINA – Media OutReach – 30 December 2022 In recent years, the opening-up of China’s capital market has been accelerating, and its international influence has been continuously enhanced. On December 30th, Southern Asset Management’s Shenzhen-Singapore ETF interoperability product, China Southern CSOP CGS-CIMB FTSE Asia-Pacific Low-Carbon Selected ETF (abbreviation: Asia-Pacific Low Carbon ETF, code: 159687), was officially listed on the Shenzhen Stock Exchange. On the same day, CSOP CSI STAR and CHINEXT 50 Index ETF (SGX: SCY) was listed in Singapore, providing diversified cross-border investment options for investors in China and Singapore.

Shenzhen-Singapore ETF exchange is another important measure for the two-way opening of China’s capital market. On the one hand, the exchange of Shenzhen-Singapore ETFs will realize the introduction of Singapore ETFs. Investors from mainland China can indirectly invest in ETF products in Singapore market in China through Shenzhen Stock Exchange, which is conducive to further enriching the cross-border fund product system, expanding investors’ cross-border investment channels and meeting the diversified cross-border investment needs of investors from mainland China. On the other hand, the exchange of Shenzhen-Singapore ETFs will realize the “going out” of Shenzhen ETFs. As an important international financial center in Asia and even the whole world, Singapore’s capital market is an open market for global investors, with diversified sources of funds. The listing and trading of Shenzhen ETF on the Singapore Stock Exchange will provide convenient channels for overseas investors to invest in A-share ETFs, which will help broaden the overseas investment channels and customer scope of Shenzhen ETF, introduce diversified incremental funds, enrich the structure of holders, and promote the greater development of Shenzhen ETF.

The Asia-Pacific low-carbon ETF issued and traded in Southern Asset Management is not only the first Shenzhen-Singapore ETF, but also China’s first ETF in the Asia-Pacific region, covering the high-quality assets in China, Singapore, Japan, Australia, India and other markets for the first time, providing a more convenient way for investors in China to invest globally. Mainland investors in China can indirectly invest in ETF products in Singapore market through Shenzhen Stock Exchange. The “one-click” layout of Asia-Pacific low-carbon leading companies is conducive to further expanding cross-border investment channels, enriching cross-border fund product systems, and meeting the diversified cross-border investment and global asset allocation needs of mainland investors in China. With huge market capacity and close economic and trade cooperation, the economic growth in the Asia-Pacific region has been strong and full of stamina in recent years. Asia-Pacific low-carbon ETF is blessed by the economic growth and green and low-carbon transformation in the Asia-Pacific region, and have good market demand and investment prospects.

Through Shenzhen-Singapore ETF interoperability mechanism, Southern Asset Management also exported China Southern CSI STAR&CHINEXT 50 Index ETF to the Singapore market, realizing the overseas listing of China ETF. The listing of China Southern CSI STAR&CHINEXT 50 Index ETF on Singapore Exchange will facilitate foreign investors to invest in China assets through Shenzhen-Singapore ETF exchange mechanism, and share the investment opportunities of China’s new economic transformation and upgrading. At the same time, it will further enhance the global influence of China Index and ETF products, and promote the international development of China asset management institutions and capital markets.

As one of the first batches of standardized fund management companies in China, Southern Asset Management is rooted in Shenzhen, the frontier of reform and opening up, and has always adhered to the international development direction, striving to be the pioneer of opening up the capital market. It was the first fund company in the industry to obtain QDII qualification, issued the first QDII Public Offering of Fund in China, and was also the first mainland fund company to set up a subsidiary in Hong Kong. The first batch of Shenzhen-Singapore ETF interoperability products is a strong alliance between Southern Asset Management and its overseas subsidiary CSOP. As the first overseas asset management company set up by China mainland fund companies, CSOP has focused on ETF investment since its establishment, and is the leading ETF management institution in Hong Kong and even in Asia.

Hashtag: #SouthernAssetManagement

The issuer is solely responsible for the content of this announcement.

Sonexay Siphandone Elected New Prime Minister of Laos

Dr. Sonexay Siphandone
Dr. Sonexay Siphandone

Dr. Sonexay Siphandone has been elected Prime Minister of Laos after receiving nearly 100% of votes from the National Assembly.

Pathomics Health and MAHSA Health sign MOU to launch Joint Centre for Research and Diagnostics for Precision Wellness and Clinical Research

KUALA LUMPUR, MALAYSIA – Media OutReach – 30 December 2022 – Pathomics Health, an organisation with a mission to provide accessible advanced clinical diagnostics, has signed a Memorandum of Understanding (MoU) with MAHSA Health to set up a Joint Centre for Research and Diagnostics Services for Precision Wellness and Clinical Research at MAHSA Avenue.

The collaboration focuses on health and wellness screening with MAHSA Health to optimise the wellbeing of individuals in Malaysia. Clinical research will also be part of the partnership to further support clinicians in their clinical care for patients across the MAHSA Health’s network of hospitals and clinics.

Combined expertise from both parties to make a significant impact on the health and wellness of MAHSA Health’s patients and cement the Joint Centre’s position as a Centre of Excellence for genomics to support MAHSA Health in its advancement of health care services, research, and innovation in ASEAN.

The changing lifestyles of the affluent middle-class lead to the disease burden shifting from communicable diseases to non-communicable diseases (NCDs) such as diabetes, cardiovascular disease, and cancer. As the middle class becomes more aware of NCDs, there is a higher demand for health check-ups and more effective diagnostics. With the use of genomics testing advancement, individuals can now better uncover their underlying risks profile to NCDs and take more proactive actions to better manage their health.

For the past 10 years, cardiovascular disease (CVD) is among the leading causes of death and morbidity in Malaysia . CVDs ranked first among the ten principal causes of death in government hospitals (21.65%) and ranked second in private hospitals (23.79%). While elderly is at risk of developing CVDs, studies suggest that 1 in 5 heart attack patients are younger than 40 years old. It is a myth that heart attacks only occur to the old. Young adults should take proactive care of their health.1

Malaysia has one of the highest incidences of diabetes in the world. According to the Malaysian 2019 national survey report, for ≥18 years old age group, 3.6 million adults had diabetes, 49% (3.7 million) cases were undiagnosed. It is estimated that diabetes can affect 7 million of Malaysian adults, posing a major public health risk with a diabetes prevalence of 31.3%. 2

Cancer is among the most common causes of deaths in Malaysia. Most cases are only discovered at late stages resulting in poor therapy outcomes. Rising direct and indirect costs of cancers impact on both the patient and family. Approximately 45% of Malaysian cancer survivors spend over 30% of their household income for cancer care within the first year of diagnosis. Early diagnosis of cancer can lead to a better likelihood of effective treatment which in turn can increase the chances of survival, less morbidity and less therapy costs.3

In 2020, 49,000 new cancer cases were estimated in Malaysia and projected to rise to more than 66,000 per year by 2030. Approximately 50% of total cancer cases are due to breast, colorectal and lung cancers in Malaysia. The leading causes of death for Malaysian women suffering from cancer is breast and cervical cancer. The screening uptake and frequency for breast, cervical, colorectal, and prostate cancers can be better. The poor response to cancer screening can be due to a lack of awareness on the available screening methods, support from family members and family doctors.

“With the advancement of medical science, everyone should have access to precision wellness and be empowered to lead heathier lifestyle and better therapy outcomes with early interventions. The genomics profiling test is a start for an individual to better understand one’s health risks profile for Cardiovascular, Cancer and Diabetes. We have a network of healthcare professionals who will support those with high risk of NCD to take proactive family planning measures, lifestyle changes to better lower their risks. With the diverse health screening tests options, it also acts as a compass for family physicians to personalise health screening tests to better meet their patients’ unique health profile. ” Michael Tan, Director of Pathomics Health.

MAHSA Health Sdn Bhd is a Malaysia-grown company, part of MAHSA Group of Companies, which is determined to be a revolutionary leader in healthcare. Since its inception in 2017, MAHSA Health has been striving to be in the forefront of primary healthcare, focusing on family health and wellness.

Pathomics Health focuses on advanced precision medicine diagnostics & digital healthcare solutions–in particular, but not limited to cancer. Since 2016, Pathomics Health has been driving excellence to unlock actionable genomics insights to enhance patient care. Pathomics Health forged its first public private partnership with University of Malaya in 2016. In 2021, Pathomics Health was appointed by Qiagen as its preferred laboratory outsourcing next generation sequencing research solutions partner for ASEAN markets. In 2022, Pathomics Health sets up its clinical diagnostics and research facilities in Singapore, focusing on Infectious Diseases and Oncology and hereby expanding its operations from Malaysia. Pathomics Health supports the acceleration of healthcare and life science research in ASEAN markets by providing outsourcing research testing services in addition to its clinical diagnostics services. In 2022, Singviva, an insurtech partner of MY IRC Sdn Bhd, has appointed Pathomics Health as its sole genomics risk profiling diagnostics lab partner for their policy holders. To find out more about Pathomics Health’s genomics profiling tests, visit pathgene.asia.

With its latest collaboration with MAHSA, Pathomics health will provide the Malaysian public and medical tourists visiting Malaysia access to its advance health screening tools beyond genomics profiling tests services offered across MAHSA health network of primary care clinics and hospital. Pathomics health and MAHSA are committed to improve primary healthcare and push the frontiers of clinical research and advanced digital healthcare solutions in precision wellness, infectious diseases screening and pharmacogenomics.

“With the collaboration with Pathomics Health, we look forward to advancing primary healthcare in the era of precision wellness for our patients for better health outcomes. We are excited of this opportunity to make a difference in the combat of Cancer, Cardiovascular and Diabetes for Malaysians. ” Datin Dr. Maya Kumutha , Chief Executive Officer of MAHSA Health

References:
1. Int. J. Environ. Res. Public Health 2021, 18, 7941. https://doi.org/10.3390/ijerph18157941
2. Akhtar S, Nasir JA, Ali A, Asghar M, Majeed R, et al. (2022) Prevalence of type-2 diabetes and prediabetes in Malaysia: A systematic review and meta-analysis. PLOS ONE 17(1): e0263139. https://doi.org/10.1371/journal.pone.0263139
3. Ministry of Health Malaysia (2021). National Strategic Plan for Cancer Control Programme 2021-2025.
4. Cancer in My Community: Addressing Increasing Cancer Cases in Malaysia. Cancer.Net. 17 Feb 2022. Mastura Md Yusof, Wan Zamaniah Wan Ishak. Accessed on 1/09/2022.

For more information on Pathomics Health, visit website at www.pathomicshealth.com.

Hashtag: #pathomicshealth #pathgene #nextgenerationsequencing #diagnostics #healthtech #ngs #genomics #cardiovascular #oncology #cancer #diabetes #mahsa #mahsahealth #healthscreening #healthassessment #healthandwellness #wellness #healthylifestyle #investhealth ##DatinDrMayaKumutha

The issuer is solely responsible for the content of this announcement.

Pathomics Health Pte Ltd

Pathomics Health, a diagnostics and research service provider, focuses on advanced precision diagnostics and digital healthcare solutions. Its full-service CAP (College of American Pathologists)compliant laboratory deploys cutting-edge technologies that are clinically validated by international bodies such as FDA and CE-IVD. Equipped with a multi-disciplinary team of experts, Pathomics Health’s customers and patients receive high-quality diagnostics reports for better management of patient care and health outcomes. In 2017, the University of Malaya and Pathomics Health established GEMS@UM, a public-private partnership, to provide patients access to cost-effective precision medicine. In 2019, Pathomics Health established its regional headquarters in Singapore. In 2022, Pathomics Health is expanding its laboratory operations from Malaysia to Singapore.

Spackman Media Group Artist Wi Ha-Jun Wins Rising Star Award In 2023 Korea First Brand Awards

  • Spackman Media Group artist Wi Ha-jun awarded the Rising Star Award in the 2023 Korea First Brand Awards conducted by the Korea Consumer Forum
  • Award follows Wi Ha-jun’s latest chart-topping Netflix drama, LITTLE WOMEN, which ranked first in Taiwan, Indonesia and Japan and 8th globally on Netflix, according to Flixpatrol.com as of October 8, 2022
  • Previously, Wi Ha-jun starred in the original Korean series, SQUID GAME (2021), the #1 Netflix show across over 90 countries, including the US and Korea

SINGAPORE – Media OutReach – 30 December 2022 Spackman Entertainment Group Limited (the “Group“), one of Korea’s leading entertainment production groups founded in 2011 by media & technology investor Charles Spackman, wishes to announce that Wi Ha-jun of MSteam Entertainment Co., Ltd. (“MSteam“), a wholly-owned subsidiary of the Group’s associated company, Spackman Media Group Limited (“Spackman Media Group“), was awarded the Rising Star Award in the 2023 Korea First Brand Awards conducted by the Korea Consumer Forum on December 29, 2022[1].

Conducted annually by the Korea Consumer Forum, the Korea First Brand Awards recognizes the brand reputation of various idols, actors and groups in the local entertainment sector and provides brands with a frame of reference on the popularity and loyalty of celebrities amongst consumers.

Spackman Media Group artist Wi Ha-jun’s latest Netflix drama, LITTLE WOMEN, which was filmed in Korea and Singapore, took the top spot in Taiwan, Indonesia and Japan and ranked 8th globally on Netflix, according to Flixpatrol.com as of October 8, 2022. The series featured iconic landmarks in Singapore such as Marina Bay Sands and The Fullerton Hotel.

In February 2022, Wi Ha-jun of Spackman Media Group was selected as the South Korea ambassador for Swiss luxury watchmaker, TAG Heuer. He was appointed as the ambassador for his hometown, Wando-gun of South Korea in January 2022. Previously, Wi Ha-jun starred in the original Korean series, SQUID GAME (2021), the #1 Netflix show across over 90 countries, including the US and Korea. Through his role as Hwang Jun-ho, a policeman in SQUID GAME (2021), Wi Ha-jun has emerged as an internationally recognized actor.

Wi Ha-jun also starred in highly popular K-drama BAD AND CRAZY (2021), which reached first place in viewership ratings for consecutive weekends after its release on 17 December 2021.

Wi Ha-jun was also selected as the brand ambassador for the American premium casual brand BEENTRILL and released a beauty pictorial with YSL beauty in December 2021. He also headlined in the Korean crime thriller film, MIDNIGHT (2021), which received the Best Feature Award at the 13th UK Grimmfest Film Festival.

In addition to Wi Ha-jun, MSteam represents iconic Korean actress Son Ye-jin, who starred in hit romance drama CRASH LANDING ON YOU (2020), and top actress Lee Min-jung, who won the Top Excellence Award at the 2020 APAN Star Awards.


[1] Naver.com, https://entertain.naver.com/read?oid=382&aid=0001024914&viewType=pc, Wi Ha-jun, IVE and Lim Young Woong as stars to lead in 2023, 30 December 2022

Hashtag: #SpackmanEntertainmentGroup

The issuer is solely responsible for the content of this announcement.

About Spackman Entertainment Group Limited

Spackman Entertainment Group Limited (“SEGL” or the “Company“), and together with its subsidiaries, (the “Group“), is one of Korea’s leading entertainment production groups. SEGL is primarily engaged in the independent development, production, presentation, and financing of theatrical motion pictures in Korea.

The Company was founded in 2011 by renowned media and technology investor Charles Spackman who served as the Company’s Executive Chairman until 2017. For the past two decades, Mr. Charles Spackman has been a powerhouse in the Korean entertainment industry starting in the early 2000’s with the pioneering success of Sidus Pictures, the largest movie production company at the time and the first to be listed in Korea. Mr. Spackman is also the Founder, Chairman and Chief Executive Officer of the global investment firm, Spackman Group. For more information, please visit and .

Since its founding, SEGL had produced more than 30 major motion pictures including a number of the highest grossing and award-winning films in Korea, namely #ALIVE (2020), CRAZY ROMANCE (2019), DEFAULT (2018), MASTER (2016), THE PRIESTS (2015), SNOWPIERCER (2013), COLD EYES (2013) and ALL ABOUT MY WIFE (2012).

Our films are theatrically distributed and released in Korea and overseas markets, as well as for subsequent post-theatrical worldwide release in other forms of media, including online streaming, cable TV, broadcast TV, IPTV, video-on-demand, and home video/DVD, etc. Generally, we release our motion pictures into wide-theatrical exhibition initially in Korea, and then in overseas and ancillary markets.

The Group also invests into and produces Korean television dramas. In addition to our content business, we also own equity stakes in entertainment-related companies and film funds that can financially and strategically complement our existing core operations. SEGL is listed on the Catalist of the Singapore Exchange Securities Trading Limited under the ticker 40E.

Production Labels

SEGL owns a 100% equity interest in Studio Take Co., Ltd. (“Studio Take“) which produced STONE SKIPPING (2020) and THE BOX (2021). Its latest film, A MAN OF REASON, is set to be screened theatrically and digitally in North America in the first quarter of 2023 and at theatres in Korea in the fourth quarter of 2022 or first quarter of 2023. A MAN OF REASON premiered in the US at the 42nd Hawaii International Film Festival. The film was also invited to the 47th Toronto International Film Festival, the largest film festival in North America, and the 55th Sitges Film Festival, one of the world’s top three genre film festivals. Studio Take shall also release an upcoming film, THE GUEST, in 2023 tentatively.

SEGL owns Novus Mediacorp Co., Ltd. (“Novus Mediacorp“), an investor, presenter, and/or post-theatrical distributor for a total of 80 films (59 Korean and 21 foreign) including OKAY MADAM (2020), LONG LIVE THE KING (2019), MY FIRST CLIENT (2019), ROSE OF BETRAYAL (2018), THE OUTLAWS (2017) and SECRETLY, GREATLY (2013), which was one of the biggest box office hits of 2013 starring Kim Soo-hyun of MY LOVE FROM THE STARS (2013), as well as FRIEND 2: THE GREAT LEGACY (2013). In 2012, Novus Mediacorp was also the post-theatrical rights distributor of ALL ABOUT MY WIFE (2012), a top-grossing romantic comedy produced by Zip Cinema. In 2018, THE OUTLAWS, co-presented by Novus Mediacorp broke the all-time highest Video On Demand (“VOD“) sales records in Korea. For more information, please visit

The Company owns a 100% equity interest in Greenlight Content Limited (“Greenlight Content“) which is mainly involved in the business of investing into dramas and movies, as well as providing consulting services for the production of Korean content. Through the acquisition of Greenlight Content, the Group’s first co-produced drama, MY SECRET TERRIUS, starring top Korean star, So Ji Sub, achieved #1 in drama viewership ratings for its time slot and recorded double digits for its highest viewership ratings. Greenlight Content was one of the main investors of MY SECRET TERRIUS.

The Company owns a 100% equity interest in Simplex Films Limited (“Simplex Films“) which is an early stage film production firm. The maiden film of Simplex Films, JESTERS: THE GAME CHANGERS (2019), was released in Korea on 21 August 2019. Simplex Films has several line-up of films including HURRICANE BROTHERS (working title).

The Company owns a 20% equity interest in The Makers Studio Co. Ltd., which plans to produce and release four upcoming films, the first of which will be THE ISLAND OF THE GHOST’S WAIL, a comedy horror film.

Talent Representation

The Company holds an effective shareholding interest of 43.88% in Spackman Media Group Limited (“SMGL“). SMGL, a company incorporated in Hong Kong, together with its subsidiaries, is collectively one of the largest entertainment talent agencies in Korea in terms of the number of artists under management, including some of the top names in the Korean entertainment industry. SMGL operates its talent management business through renowned agencies such as SBD Entertainment Inc. (Son Suk-ku, Han Ji-hyun, Park Keun-rok), MSteam Entertainment Co., Ltd. (Son Ye-jin, Wi Ha-jun, Lee Min-jung, Ko Sung-hee, Lee Cho-hee), UAA&CO Inc. (Kim Sang-kyung) and Play Content Co., Ltd. (Hwang-hwi). Through these full-service talent agencies in Korea, SMGL represents and guides the professional careers of a leading roster of award-winning actors/actresses in the practice areas of motion pictures, television, commercial endorsements, and branded entertainment. SMGL leverages its unparalleled portfolio of artists as a platform to develop, produce, finance and own the highest quality of entertainment content projects, including theatrical motion pictures, variety shows and TV dramas. This platform also creates and derives opportunities for SMGL to make strategic investments in development stage businesses that can collaborate with SMGL artists. SMGL is an associated company of the Company. For more information, please visit

The Company owns a 100% equity interest in Constellation Agency Pte. Ltd. (“Constellation Agency“). Constellation Agency, which owns The P Factory Co., Ltd. (“The P Factory“) and Platform Media Group Co., Ltd. (“PMG“), is primarily involved in the business of overseas agency for Korean artists venturing into the overseas market. The P Factory is an innovative marketing solutions provider specializing in event and branded content production. PMG is a talent management agency which represents and manages the careers of major artists in film, television, commercial endorsements and branded entertainment.

Strategic Businesses

The Company also operates a café-restaurant, Upper West, in the Gangnam district of Seoul and own a professional photography studio, noon pictures Co., Ltd.

For more details, please visit